Another Shkreli-like drug price controversy? Leadiant finds itself in the spotlight after 500-fold price hike — FT

Martin Shkreli may be cooling his heels in a federal prison, but the pharma pricing strategy he pursued that got him into an intense national controversy appears to be alive and well in Europe this week.